1. A genetic risk score predicts de novo hepatocellular carcinoma in hepatits c cirrhotic patients treated with direct-acting antivirals. (February 2020) Authors: Degasperi, E.; Galmozzi, E.; Pelusi, S.; D'Ambrosio, R.; Soffredini, R.; Borghi, M.; Perbellini, R.; Facchetti, F.; Iavarone, M.; Sangiovanni, A.; Valenti, L.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years. Issue 1 (February 2018) Authors: Loglio, A.; Galmozzi, E.; Iavarone, M.; Grossi, G.; Viganò, M.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients. (February 2020) Authors: Viganò, M.; Loglio, A.; Cerini, F.; Farina, E.; Facchetti, F.; Perbellini, R.; Rumi, M.G.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment. Issue 1 (February 2018) Authors: Sangiovanni, A.; D'Ambrosio, R.; Lunghi, G.; Bruccoleri, M.; Alimenti, E.; Borghi, M.; Perbellini, R.; Aghemo, A.; Iavarone, M.; Colombo, M.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Chemokine changes during direct antiviral agents (DAA) therapy in patients with HCV infection or reinfection after liver transplantation: preliminary insights on their possible correlates. (February 2019) Authors: Colucci, G.; Donato, M.F.; D'Ambrosio, R.; Invernizzi, F.; Degasperi, E.; Perbellini, R.; Lunghi, G.; Uceda, S.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN. Issue 1 (16th February 2017) Authors: D'Ambrosio, R.; Aghemo, A.; Degasperi, E.; Sangiovanni, A.; Rumi, M.G.; Fraquelli, M.; Perbellini, R.; Bedossa, P.; Colombo, M.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients. (February 2019) Authors: Degasperi, E.; Galmozzi, E.; Facchetti, F.; D'Ambrosio, R.; Soffredini, R.; Borghi, M.; Perbellini, R.; Iavarone, M.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis. (February 2019) Authors: Loglio, A.; Alexandrov, A.; Renteria, S.C. Uceda; Tham, C.Y.L.; Greco, L.; Borghi, M.; Perbellini, R.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Lecchi, L.; Prati, D.; Ceriotti, F.; Lunghi, G.; Bertoletti, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Excellent long-term virological and clinical response in HDV compensated cirrhotics treated with high dose Bulevirtide beyond 2.5 years: A case series. (March 2021) Authors: Loglio, A.; Ferenci, P.; Renteria, SC. Uceda; Holzmann, H.; Borghi, M.; Perbellini, R.; Rimondi, A.; Trombetta, E.; Giovanelli, S.; Porretti, L.; Prati, D.; Ceriotti, F.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated hbv cirrhotics treated with nuc for 10 years. (February 2020) Authors: Galmozzi, E.; Loglio, A.; Facchetti, F.; Iavarone, M.; Borghi, M.; Viganò, M.; Perbellini, R.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗